All In MedTech

Device Trial Radar · NCT07246980

Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success Study

Continuous Observational Monitoring Program for Allay™ Hydrogel Cap Safety and Success (COMPASS) Study: An Open Label Registry Study to Assess the Safety and Performance of the Allay™ Hydrogel Cap

Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

1,000

Planned (sponsor's estimate)

Start

May 6, 2026

Primary completion

Jan 1, 2029

Study completion May 1, 2029

Sponsor

Lead sponsor
Tulavi Therapeutics,Inc.Not on our public-company list
Sponsor type
Industry
First posted
Nov 24, 2025

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

is is a multi-center, open-label, observational registry study (both prospective and retrospective) designed to evaluate the safety and performance of the allay™ Hydrogel Cap. This cap is an in situ forming implantable hydrogel medical device used in various peripheral nerve surgeries, including amputation and neuroma excision. The study aims to gather demographic, operative, and clinical outcomes data from patients who have received the device. The primary endpoints focus on the device's clinical performance, assessed using patient-reported outcomes (PROs). These include tracking changes in pain scores, pain intolerance, and cold intolerance, as well as the incidence of neuroma recurrence and changes in pain medication use from baseline. Secondary endpoints concentrate on safety, monitoring the incidence of device failures, surgical complications, unplanned re-operations, and unexpected adverse device events (UADEs) within the study population. Essentially, the registry is collecting real-world data to determine how well and how safely the allay™ cap performs in a clinical setting.

Conditions

  • Peripheral Nerve Injuries

Interventions

  • Nerve CapDevice

    Patients who have or will receive allay Hydrogel Cap

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of change in Pain Scores from baseline using VASTime frame: Baseline (Pre Surgery ), 2 Weeks, 1 month, 4 month, 12 month and 24 month (Post Surgery)
  2. Assessment of change in Pain scores from baseline using Numerical Rating ScaleTime frame: Baseline (Pre Surgery ), 2 Weeks, 1 month, 4 month, 12 month and 24 month (Post Surgery)
  3. Assessment of change in Pain Interference from baseline using PROMIS PI Short Form 5bTime frame: Baseline (Pre Surgery ), 2 Weeks, 1 month, 4 month, 12 month and 24 month (Post Surgery)

3 more outcomes with a free account

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Kaiser Permanente

    Redwood City, California · Recruiting

  • University of Colorado Anschutz.

    Englewood, Colorado · Recruiting

  • Orlando Health

    Orlando, Florida · Recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.